Exploring the Benefits of Ruxolitinib in Second-Line Polycythemia Vera
Srdan Verstovsek, MD, PhD, discusses the use of ruxolitinib as a second-line treatment of patients with polycythemia vera.
Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the use of ruxolitinib (Jakafi) as a second-line treatment for patients with polycythemia vera (PV).
For the second-line setting in PV, patients typically have a shorter survival, said Verstovsek. At this stage, the disease is more aggressive and a second line of therapy is needed.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
